Pediatric Puzzler: Lymphadenopathy and nosebleeds in 2-year-old girl: Is anything as it seems?

Article

A 2-1/2-year-old girl's adenopathy has not subsided five days after initiation of antibiotic therapy with amoxicillin and clavulanate potassium (Augmentin). And lately, she seems to be having "a lot" of nosebleeds.

Recent Videos
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Jesse Hinckley, MD, PhD
Validating digital stethoscope for pediatric breath sounds, with Jennifer Nestor, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Sensory play for children with autism, with Joshua Feder, MD
Stephanie Chao, MD
Feasibility of ambulatory blood pressure monitoring in primary care | Carissa Baker-Smith, MD, MPH
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
Related Content
Breakfast: Still the most important meal of the deal? | Image credit: Colleen Sloan

Breakfast: Still the most important meal of the day?

Colleen Sloan, PA-C, RDN
May 2nd 2025
Article

Colleen Sloan, PA-C, RDN, shares the importance of breakfast and the reasoning to why kids skip this essential meal.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA news in pediatrics: April 2025 | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA news in pediatrics: April 2025

Morgan Ebert, Managing Editor
May 1st 2025
Article

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from April 2025.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Lea Widdice, MD, director, Adolescent Medicine Fellowship; associate professor, University of Cincinnati Department of Pediatrics, Cincinnati, Ohio.

Uncovering the pediatrician's role in OTC STI testing, with Lea Widdice, MD

Lea Widdice, MD
April 30th 2025
Article

Lea Widdice, MD, details her recent presentation at PAS 2025 on OTC STI testing within pediatrics.

Elamipretide to treat Barth syndrome sees FDA target action delay | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

Elamipretide to treat Barth syndrome sees FDA target action delay

Joshua Fitch, Senior Editor
April 30th 2025
Article

Stealth BioTherapeutics' CEO stated, "We hope to gain more information on the revised action date in the coming days."

© 2025 MJH Life Sciences

All rights reserved.